期刊
NATURE BIOMEDICAL ENGINEERING
卷 -, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-019-0498-9
关键词
-
资金
- Wyss Institute for Biologically Inspired Engineering at Harvard University
- Defense Advanced Research Projects Agency [W911NF-12-2-0036]
- US Food and Drug Administration [HHSF223201310079C]
- Knut och Alice Wallenberg's stiftelse [2015-0178]
- National Science Foundation [1541959]
- Harvard University, the Harvard Materials Research Science and Engineering Center [DMR-1420570]
Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) performed in animals are often not predictive of drug PKs and PDs in humans, and in vitro PK and PD modelling does not provide quantitative PK parameters. Here, we show that physiological PK modelling of first-pass drug absorption, metabolism and excretion in humans-using computationally scaled data from multiple fluidically linked two-channel organ chips-predicts PK parameters for orally administered nicotine (using gut, liver and kidney chips) and for intravenously injected cisplatin (using coupled bone marrow, liver and kidney chips). The chips are linked through sequential robotic liquid transfers of a common blood substitute by their endothelium-lined channels (as reported by Novak et al. in an associated ) and share an arteriovenous fluid-mixing reservoir. We also show that predictions of cisplatin PDs match previously reported patient data. The quantitative in-vitro-to-in-vivo translation of PK and PD parameters and the prediction of drug absorption, distribution, metabolism, excretion and toxicity through fluidically coupled organ chips may improve the design of drug-administration regimens for phase-I clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据